ASCO: Combo Extends PFS in Relapsed Myeloma CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed. Jun 05, 2014
OncoBriefs: Myeloma Tx, In Situ Melanoma Superficial melanoma conferred a risk of recurrent invasive melanoma similar to that of primary invasive melanoma, Australian investigators reported. The study is one of several oncology-related news items summarized in OncoBriefs. Mar 23, 2014
Infection High in Myeloma, with High Mortality ATLANTA -- More than a fifth of patients with multiple myeloma died of infection within a year of diagnosis, Swedish investigators reported here. Dec 14, 2012
Oral Azacitidine Safe, Effective in Low-Risk MDS ATLANTA -- Oral azacitidine (Vidaza) given for up to 21 days per 4-week cycle for myelodysplastic syndrome appeared safe and effective in patients with lower-risk disease, a researcher said here. Dec 14, 2012
FDA: Revlimid Linked to Second Cancers Treatment of multiple myeloma with lenalidomide (Revlimid) as maintenance therapy is associated with an increased risk of second primary cancers, the FDA warned. May 08, 2012
Clinical Notes: Beware the Seat Heater 番茄社区app debuts a new regular feature, a roundup of clinical news you might otherwise have missed. This week we led with a report that heated car seats can leave passengers with "toasted skin syndrome." Feb 26, 2012
Withdrawal Tough With Novel Drug for Myelofibrosis The novel Janus kinase (JAK) inhibitor ruxolitinib relieves myelofibrosis symptoms, but withdrawal from the drug can be severe, researchers warned. Oct 13, 2011
Medicare to Cover More PET Scans for Cancer Diagnosis BALTIMORE -- The Centers for Medicare and Medicaid Services announced expanded coverage of PET scans for Medicare patients suspected of having most cancers. Apr 07, 2009